Argent Biopharma Ltd · ASX:RGT
Argent Biopharma — MGC Pharmaceuticals — Investor Presentation (May 2015)
16 slides from Argent Biopharma's investor presentation, May 2015
Slide 1: Investment in MGC Pharmaceuticals
Investment in MGC Pharmaceuticals Investor Presentation May 2015
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Erin Resources Limited (“Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any
Slide 3: Transaction Overview
Transaction Overview Erin Resources Limited has entered into a binding heads of agreement under which it has the exclusive option to acquire 100% of the issued capital in MGC Pharmaceuticals Pty Ltd (MGC), an Israeli based medical and cosmetic cannabis company Capital Structure − post MGC acquisitio
Slide 4: Company Overview MGC Pharmaceuticals
Company Overview MGC MGC Pharmaceuticals Limited (MGC), is an Israeli medical and cosmetic cannabis company Pharmaceuticals with over 40 years of technical and commercial Capitalizing on brand experience in the medical and cosmetics Israel – world leaders in cannabis industry the production of medic
Slide 5: Investment Highlights
Investment Highlights • Strategically positioned to exploit the rapidly growing demand for medical cannabis (worth US$2.7bn) and CBD in the cosmetic markets (estimated at US$270 billion, globally and $70 billion in Europe alone in 2014) • Unique genetics from exclusive strain of Cannabis Sativa comp
Slide 6: Industry Leading Expertise and Experience
Industry Leading Expertise and Experience Nativ Segev Roby Zomer Mr. Yaron Blubshtin Co-Founder and Co-Founder and Director Chief Agronomist / Managing Director of Business Development Advisor Nativ Segev was the CEO of Mr. Zomer brings a wealth of Yaron Blubshtin holds over 45 Israel’s second large
Slide 7: Key Milestones
Key Milestones Completion of license to grow in the EU Establishment of growing operation and planting of first crop H2 2015 Joint Venture agreement for R&D H2 2015 First harvest and extraction of CDB resin in 2016 First sales and revenue generation for the business in H2 2016 Cashflow breakeven in
Slide 8: Business Development Activities and Pipeline
Business Development Activities and Pipeline Register genetic bank Begin first First revenues in Israel and cultivation and from off-take the EU extraction agreement Jun 2015 H1 2016 H2 2016 H2 2015 H1 2016 Aug 2016 Establish Apply for and Establish growing obtain outdoor growing protocols and growi
Slide 9: Global Market Opportunity − Pharmaceuticals
Global Market Opportunity − Pharmaceuticals • Cannabinoids are legal in 23 U.S states and the MC market is estimated to be worth USD$2.7 billion globally in 2014 and US$10 billion by 2019 • In Canada the market for medical cannabis is expected to grow to US$1.3Bn in 2024, from $144m in 2014 • In Eur
Slide 10: Global Market Opportunity − Cosmetics
Global Market Opportunity − Cosmetics • In 2013 the cosmetics industry was worth US$270 billion - over 100 times that of the medical marijuana industry for 2014. • The skin care market is estimated to account for 37% of the cosmetics market, globally, c.US$100 billion • In Europe alone the cosmetics
Slide 11: Global Cannabidiol (CBD) Potential
Global Cannabidiol (CBD) Potential • Found only in cannabis plants, Cannabidiol (CBD) is the non-psychoactive ingredient • Impacts pathways in the body, which control pain and support the immune system, thereby delivering significant medicinal benefits in the treatment of chronic pain • It has a des
Slide 12: High CBD Cannabis Sativa
High CBD Cannabis Sativa Wider Market Legality CBD Cannabis Sativa legally produced - under Cannabis license Legal in 23 states in the U.S 04/11/2026 Private & Confidential 12
Slide 13: CBD Market Expected to Grow
CBD Market Expected to Grow US$ millions Canada U.S Europe Canada 10.2 10 CAGR +30% 6.8 U.S CAGR +45% Europe 2.3 CAGR +10% 0.6 0.2 E2014 E2018 04/11/2026 Private & Confidential 13
Slide 14: Licensing
Strategic and Focused Business Plan Licensing Register Good License strains and Register High CBD Manufacturing guidelines to growing strains in Europe Practice (GMP) operations in Europe First revenues via off-take Apply for additional Growing Establish Sativa agreements of first growing licenses G
Slide 15: Commercialisation Model
Commercialisation Model MGC will establish and franchise its own genetics for growing projects, which will contribute to the security of production chain. Licensing and Labs Growing Operations (near term) (long-term) $0.5 million for $3-4 million for comprehensive growing establishment of MGC first
Slide 16: Investment Summary
Investment Summary • Strategically positioned to exploit the rapidly growing demand for medical cannabis (worth US$2.7bn) and CBD in the cosmetic markets (estimated at US$270 billion, globally and $70 billion in Europe alone in 2014) • Unique genetics from exclusive strain of Cannabis Sativa compris
MGC Pharmaceuticals — Investor Presentation (May 2015) on 6ix